Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | STAT1 | P42224 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10855235 | 0.86 | DHODH (0.51) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL2535567 | 0.85 | LMNA (0.56) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL11789499 | 0.85 | NPSR1 (0.50) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL10961083 | 0.85 | NPSR1 (0.50) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL20418823 | 0.84 | GAA (0.55) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL3606132 | 0.84 | SMN1; SMN2 (0.39) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL11791077 | 0.82 | MAPT (0.52) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL583356 | 0.82 | NPSR1 (0.48) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL583369 | 0.80 | GAA (0.70) | DHODHNPSR1SMN1; SMN2GAAMAPT | |
| SCHEMBL6289967 | 0.79 | LMNA (0.71) | DHODHNPSR1SMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560974-B1 | PYRRAZOLOPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-01-27 | — | — | EP | disclosed |
| US-8487102-B2 | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2560974-A1 | PYRRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| EP-2124944-B1 | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | disclosed |
| WO-2011131571-A1 | PYRRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257402-A1 | PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| US-7915286-B2 | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| EP-1113796-A4 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6326379-B1 | ERECTILE DYSFUNCTION; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. | 2001-12-04 | — | — | US | disclosed |
| US-6316438-B1 | Fused pyridopyridazine inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB CO. | 2001-11-13 | — | — | US | disclosed |
| EP-1113796-A1 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015222-A1 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| US-4012373-A | ANTIINFLAMMATORY, CNS DEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1977-03-15 | — | — | US | disclosed |
| US-3983128-A | CNS DEPRESSANTS, ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-09-28 | — | — | US | disclosed |
| US-3979399-A | ATARACTIC, ANALGESIC, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3966746-A | ATARACTIC, ANALGESIC, HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257402-A1 | PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, GRIN3A, TACR1 | DHODH 2557/4885NPSR1 8/4885SMN1; SMN2 4700/4885 |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3B, PDE4B | DHODH 732/4885NPSR1 2185/4885SMN1; SMN2 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.